← Evidence library

BIB_382

Adjuvant pembrolizumab at Stage IIB/IIC melanoma — NMSC-protective effect (KEYNOTE-716 secondary analysis, Leachman 2026 JAMA Netw Open, n=976): total new skin cancers 7.6% (pembro) vs 11.5% (placebo); BCC halved (3.9% vs 5.3%); SCC halved (1.8% vs 3.5%); RFS benefit sustained at 52.8-month median follow-up (HR 0.62, 95% CI 0.50–0.78; DMFS HR 0.59, 0.45–0.77). ALSO: KEYNOTE-942/intismeran autogene (mRNA-4157) 5-year update (January 2026): personalised neoantigen vaccine + pembro maintains RFS HR 0.510 (0.294–0.887) at 5 years in Stage III/IV melanoma; INTerpath-001 Phase 3 (n=1,089 Stage II–IV…

Evidence grade

A

Tier

1 (Leachman 2026 JAMA Netw Open — Tier 1 journal; secondary analysis of Phase 3

Cited by tasks

05a, 17, 18, 19a

Identifiers

PMC10667090 · DOI:10.1001/jamanetworkopen · PMID:40198940

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_382/findings.md (research corpus). This page is a short context summary — not individualised medical advice.